COMMUNIQUÉS West-GlobeNewswire

Invitation: Terveystalo H1 Result – Webcast and Conference Call on 8 August 2019
05/08/2019
Terveystalo Plc will publish its half-year report for 2019 on 8 August at 9:00 EEST. (Finnish time). Materials are available after publication at: https://www.terveystalo.com/en/investors/Financial-information/ [...]
Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)
05/08/2019
Primary efficacy endpoint met with 95% reduction in gastrointestinal tissue eosinophils vs. 10% increase on placebo (p < 0.0001) Treatment response secondary endpoint met with 69% of AK002 treated patients meeting [...]
Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update
05/08/2019
NEW HAVEN, Conn., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the [...]
CADScor®System – Significantly more effective than current practice
05/08/2019
Press release Malmö August 5, 2019 CADScor®System – Significantly more effective than current practice Acarix AB (publ) (ACARIX: FN Stockholm) today announced the publication of a meta-analysis including 2245 patients [...]
Quotient Limited Provides Updates on European Hypercare Launch, the CE Mark Submission and U.S. Field Trial for the Initial Serological Disease Screening Microarray, and Reports First Quarter Fiscal 2020 Results
05/08/2019
First European hypercare launch site initiated following CE mark approval Initial Serological Disease Screening microarray submitted for CE marking U.S. field trial activities for initial Serological Disease Screening [...]
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2019
05/08/2019
RANCHO CUCAMONGA, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2019 ended June 30, 2019, after the [...]
Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer
05/08/2019
Dr. Amado’s Addition to the Senior Leadership Team Reunites Him with Former Colleagues in the Pursuit of Novel Immunotherapies SOUTH SAN FRANCISCO, Calif, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. ( [...]
Nexstim NBT® system authorized for commercial distribution in Australia
05/08/2019
Press release, Helsinki, 5 August 2019 at 1 pm (EET) Nexstim NBT ® system authorized for commercial distribution in Australia Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") - the targeted neuromodulation [...]
Share buy-back week 31/2019
05/08/2019
Announcement 5 August 2019 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling [...]
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
05/08/2019
LONDON, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a dry powder [...]
AB Science provides an update on its masitinib clinical program
05/08/2019
Paris, August 5 2019, 7.30am Update on masitinib clinical program AB Science SA (NYSE Euronext - FR0010557264 - AB) provides an update on its masitinib clinical program. The key points of the masitinib clinical program [...]
AB Science fait le point sur le programme clinique du masitinib
05/08/2019
Paris, 5 août 2019, 7h30 Point sur le programme clinique du masitinib AB Science SA (NYSE Euronext - FR0010557264 - AB) fait le point sur le programme clinique du masitinib. Les points principaux du programme clinique [...]
IBA signs contract to install Cyclone® 70 system in South Korea
05/08/2019
Cyclone ® 70 will be used as a high energy, high intensity proton “driver” for a large science project for rare isotopes Louvain-la-Neuve, Belgium 5 th 2019 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s [...]
IBA signe un contrat pour l’installation d’un Cyclone® 70 en Corée du Sud
05/08/2019
Le Cyclone ® 70 sera utilisé comme source de protons haute énergie et haute intensité pour un vaste projet scientifique sur les isotopes rares Louvain-la-Neuve, Belgique, 5 août 2019 - IBA (Ion Beam Applications S.A., [...]
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Comprehensive Corporate Update
05/08/2019
Tuesday, August 13, 2019, 8:00 a.m. EDT NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly [...]
Study on Performance Data of Idylla™ NRAS-BRAF Mutation Assay at 71st AACC Annual Scientific Meeting in Anaheim, CA (US)
05/08/2019
PRESS RELEASE 5 August 2019, 07:00 CEST (4 August 2019, 22:00 PDT) Study on Performance Data of Idylla™ NRAS-BRAF Mutation Assay at 71st AACC Annual Scientific Meeting in Anaheim, CA (US) Mechelen, Belgium, 5 August [...]
ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019
05/08/2019
Geneva, Switzerland and Boston, MA – August 5, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for [...]
Fagron NV: Turnover increase of 10.6%; REBITDA increased to €55.6 million
05/08/2019
Regulated information Nazareth (Belgium)/Rotterdam (Netherlands), 5 August 2019 Turnover increase of 10.6%; REBITDA increased to €55.6 million Acquisitions strengthen market position in Latin America and Europe New [...]
Roche’s Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer
05/08/2019
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer Data will be shared with health authorities globally, including the U.S. Food and [...]

Pages